anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Spinocerebellar ataxia type 3 (SCA3) is the most common type of disease related to poly-glutamine (polyQ) repeats. Its hallmark pathology is related to the abnormal accumulation of ataxin 3 with a longer polyQ tract (polyQ-ATXN3). However, there are other mechanisms related to SCA3 progression that require identifying trait and state biomarkers for a more accurate diagnosis and prognosis. Moreover, the identification of potential pharmacodynamic targets and assessment of therapeutic efficacy necessitates valid biomarker profiles. The aim of this review was to identify potential trait and state biomarkers and their potential value in clinical trials. Our results show that, in SCA3, there are different fluid biomarkers involved in neurodegeneration, oxidative stress, metabolism, miRNA and novel genes. However, neurofilament light chain NfL and polyQ-ATXN3 stand out as the most prevalent in body fluids and SCA3 stages. A heterogeneity analysis of NfL revealed that it may be a valuable state biomarker, particularly when measured in plasma. Nonetheless, since it could be a more beneficial approach to tracking SCA3 progression and clinical trial efficacy, it is more convenient to perform a biomarker profile evaluation than to rely on only one.
PROBLEM TO BE SOLVED: To obtain a new compound useful for obtaining as a high purity crystal not affected by color development due to reaction a compound having excellent cholecystokinin antagonistic action and useful as a prophylactic and therapeutic agent for a pancreatic lesion or the like. SOLUTION: This new compound is expressed by formula I (wherein R is cyano or the like) and is e.g. (S)-3- 1-(2-fluorophenyl)-2,3-dihydro-3-[(3- isoquinolinyl)carbonyl]amino-6-methoxy-2-oxo-1H-indol-3-yl}propionitri le.(-)-10- camphor-sulfonate. The compound of formula I is obtained by making a compound of formula II act on (-)-10-camphor-sulfonic acid in an equimolar state. The reaction is carried out by stirring the reactant in an adequate solvent at 0-50 deg.C for 1-5 h. and the reaction product is easily precipitated by adding the seed crystal. By using the compound of formula I as a production intermediate, the compound of formula II having a purity of >=99.9% is obtained.
Obese Black individuals have a higher prevalence of insulin resistance, which is linked to an elevated risk of cardiometabolic diseases and cardiovascular disease. The reasons behind the increased insulin resistance in this group are not fully understood. Key to regulating glucose metabolism and the overall balance of energy, the cyclic guanosine monophosphate (cGMP) pathway is crucial for maintaining cardiometabolic health. Research indicates that both Black race and obesity are associated with reduced levels of upstream regulators of cGMP activity, including natriuretic peptides (NPs) and nitric oxide (NO). This reduced level of NPs and NO predisposes Black obese individuals to decreased cGMP activity, potentially contributing to the higher occurrence of cardiometabolic diseases seen in this population. Vericiguat, a drug that stimulates the soluble guanylate cyclase, thereby enhancing cGMP activity independently of NO, presents a novel approach to improving cardiometabolic health in those most at risk due to low cGMP activity. This study hypothesizes that directly augmenting cGMP levels with vericiguat will improve cardiometabolic health parameters including insulin sensitivity and energy expenditure in Black obese adults with insulin resistance. Investigators plan to execute a placebo-controlled randomized trial targeting Black obese participants with insulin resistance to examine whether vericiguat can (1) improve insulin sensitivity and (2) increase resting energy expenditure. For the first aim, Investigators aim to enroll 200 Black obese (BMI≥30 kg/m\^2) individuals with a HOMA-IR of ≥2.5, randomizing them to either vericiguat 10 mg once daily or a placebo once daily in a double-blind setup for 12 weeks. Investigators will assess improvements in insulin sensitivity through euglycemic hyperinsulinemic clamp and compare the results between the vericiguat and placebo groups after 12 weeks. For the second aim, Investigators will evaluate changes in resting and exercise energy expenditure across both groups over the same period. An exploratory objective will investigate changes in brown adipose tissue volume and activity using PET-MRI, as well as UCP1 gene expression in white adipose tissue, in a subset of 100 participants after 12 weeks of vericiguat treatment. This will offer insights into the mechanisms by which cGMP augmentation may facilitate improvements in cardiometabolic health. By focusing on the direct enhancement of cGMP activity in Black obese individuals, this study proposes a novel targeted therapeutic strategy aimed at improving cardiometabolic health and addressing the increasing prevalence of cardiometabolic disease in the Black population.
PURPOSE: To produce a metal base composite with uniformly dispersed hard grains by classifying metal powder into plural classes, mixing the metal powder with the hard grains starting from the small grain diameter class toward the larger diameter class in order and hot-caking, when the herd grains of a small diameter are mixed with the matrix metal powder having a larger diameter. CONSTITUTION: The hard grains B having 10? or small average grain diameter and the matrix metal powder A having larger average grain diameter than the hard grains, are mixed and hot-caked to produce the grain dispersed metal base composite. Then, the metal powder A is classified into A1, A2...An and at first, the metal powder A1 having the smallest grain diameter (the max. grain diameter is 13 or less times of the hard grains) is mixed with the hard grains B in the dry condition, and with this mixed powder C1, the metal powder A2 having the successively smallest grain diameter is mixed in the dry condition. In such a way, until the metal powder An having the largest grain diameter is mixed with the mixed powder in the dry condition in order, and the mixed powder Cn is hot-caked to a prescribed shape to produce the granular dispersion metal base composite having ?-0.5 or a larger dispersion degree D. By this method, the high performance of the composite having excellent strength and cold forgability is obtd[JPS6041656A]
Patients receive PO BID on days 1-28, bendamustine IV on days 1 and 2, and rituximab IV on day 1 or 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients receive acalabrutinib PO BID on days 1-7 and 22-28, rituximab IV on day 1, and cytarabine IV Q12 hours on days 1 and 2. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
Using the Olink Explore 1536 platform, we measured 1,463 unique proteins in 303 cerebrospinal fluid (CSF) specimens from four clinical centers contributed by uninfected controls and 12 groups of people living with HIV-1 infection representing the spectrum of progressive untreated and treated chronic infection. We present three initial analyses of these measurements: an overview of the CSF protein features of the sample; correlations of the CSF proteins with CSF HIV-1 RNA and neurofilament light chain protein (NfL) concentrations; and comparison of CSF proteins in HIV-associated dementia (HAD) and neurosymptomatic CSF escape (NSE). These reveal a complex but coherent picture of CSF protein changes with highest concentrations of many proteins during CNS injury in the HAD and NSE groups and variable protein changes across the course of systemic HIV-1 progression that included two common patterns, designated as lymphoid and myeloid patterns, related to principal involvement of their underlying inflammatory cell lineages. Antiretroviral therapy reduced CSF protein perturbations, though not always to control levels. The dataset of these CSF protein measurements, along with background clinical information, is posted online. Extended studies of this unique dataset will supplement this report to provide more detailed characterization of the dynamic impact of HIV-1 infection on the CSF proteome across the spectrum of HIV-1 infection, advancing the mechanistic understanding of HIV-1-related CNS pathobiology.
Stroke is the leading cause of disability in the United States, and in 25% of cases directly attributable to cigarette smoking. While persistent disability is often attributed to arm or leg weakness, respiratory muscle weakness also impedes post-stroke rehabilitation, reduces quality of life, and increases risk of post-stroke health complications. The investigators' central hypothesis for this pilot study is that a combined Exercise Program (EP) with Respiratory Strength Training (RST) improves physiologic, activity and societal participation outcomes in chronic stroke survivors. Individuals with chronic stroke, with and without smoke exposure will be randomized to an experimental EP + Respiratory Strength Training (RST) group or an active control EP + Respiratory Relaxation training (RRT) group. The EP consists of strengthening, cardiovascular and stretching exercises. The experimental RST consists of resisted inspiration and expiration using an adjustable threshold training device. The active control RRT participants will use a device modified to minimize resistance. Subjects will participate in 24 supervised intervention sessions (3x/week for 8 weeks) and undergo assessments of physiologic system impairment (maximum inspiratory and expiratory pressure, activity (number of steps per day), and societal participation (number of trips outside the home) pre-intervention, at the 4-week midpoint and post-intervention at 9 weeks. The investigators will follow participants for 1-year via monthly phone calls to assess respiratory complication incidence. To investigate the intervention effects for EP/RST vs EP/RRT, the investigators will adopt a mixed effects statistical model to account for the correlation of repeated measurements within each participant. This innovative work will provide the first controlled, empirical evidence concerning the rehabilitative effects of combined EP and RST in those with and without smoking exposure. These data will be instructive to meet a current unmet rehabilitative need, to promote patient-centered care and contribute to decreasing morbidity and mortality for post-stroke Floridians.
The purpose of this study is to assess the effects of 35 EECP sessions on cardiopulmonary training performance in healthy volunteers. Prior published and anecdotal evidence suggests that EECP should improve athletic performance. Data from this study will be used to generate sample size and power calculations for feasibility of future EECP studies. The results of this study could provide evidence that can help active duty and Department of Defense beneficiaries optimize physical conditioning, endurance and overall health. It could help active duty members maximize their physical training potential enabling them to better prepare for missions down range. Additionally, physiologic cardiopulmonary improvements may have the potential to decrease the conditioning time required for injured, post-operative and post-partum active duty members to return to duty.
This multi-center, prospective, observational (non-interventional) study is the second in a series to measure structural parameters of the optic nerve head, the peripapillary retinal nerve fiber layer, and the macula using the Heidelberg Spectralis OCT device. This study is conducted in normal Japanese volunteers. The main goal of the study is to provide the range of these structural parameters in normal eyes. The study will include at least 224 (enrollment target: 249) normal volunteers; each study site will recruit 32 to 40 subjects with an age range of 18 to 90 years and an approximately equal number of females and males. All subjects will undergo Spectralis OCT imaging, biometric and ophthalmoscopic examination, disc photography and visual field testing in one single visit. All examinations performed on the subjects are non-significant risk procedures because the medical devices are cleared for marketing in Europe and in the U.S.
PROBLEM TO BE SOLVED: To provide fatty acid derivatives with hyaluronan synthase inducing action and to provide a production method thereof.SOLUTION: The invention relates to fatty acid derivatives forming ester bond with fatty acid, fructose, and galactose. The fatty acid derivatives are produced by enzyme reaction during fermentation. The fatty acid derivatives increase hyaluronan synthase of epidermal cells and osteoblasts in the skin to increase hyaluronic acid. The production method thereof comprises adding Bacillus natto. of Nattomoto Hompo and Monascus of Beni Kouji Hompo to Psophocarpus tetragonolobus seeds to ferment, and treating the fermented liquid with protease. The fatty acid derivatives obtained show an excellent effect, and are applied as cosmetics, food formulations, and pharmaceuticals.SELECTED DRAWING: None
The utility model discloses a calcium ion powder capsule which comprises a capsule shell and calcium ion powder. The capsule shell includes a left capsule shell (1) and a right capsule shell (2). A left inner cavity (3) with a right opening is reserved in the left capsule shell (1). A right cavity (4) with a left opening is reserved in the right capsule shell (2). The outer wall of the right end of the left capsule shell (1) is matched with the inner wall of the left end of the right capsule shell (2). The right end of the left capsule shell (1) is inserted into the left end of the right capsule shell (2) in an elastic contact manner. A capsule inner cavity is formed by the left inner cavity (3) and the right inner cavity (4). The calcium ion powder (5) is loaded into the capsule inner cavity. By using a capsule to contain the calcium ion powder, small-dose packaging is achieved, and the calcium ion powder is prevented from oxidation caused by air contact before the calcium is dissolved in water. In addition, a preparation technique of the calcium ion powder capsule is easy to master, and processing is simple.
All patients will receive a starting dose of sorafenib 400 mg by mouth twice daily. At four weeks, all patients who have not experienced Grade 3 or 4 toxicity will undergo dose escalation using a treatment schedule of days 1-5 days of each week. Doses will continue to be escalated every 4 weeks depending on tolerability and tumor response.
In the control-group, we used a mono-frequency device (ROLAND, RT-20 series, frequency=1MHz). We treated an area of 5cm2, softly moving the US-probe around the most painful point of the greater trochanter at the clinical palpation. UST was supplied in a continuous modality, with an intensity of 1.5 W/cm2, for ten consecutive daily sessions of ten minutes each.
PURPOSE:To provide a stable bead carrier for cell culture, composed of a water- insoluble polymer substituted with a compound having primary amino group or primary and secondary amino groups, and having excellent performance in the culture of anchorage dependent cell. CONSTITUTION:The objective bead carrier for cell culture is composed of a water-insoluble polymer substituted with a compound having primary amino group of formula -O-R-NH2 (R is substituted or unsubstituted alkyl, or alkyl having -NH- in the main chain) or primary and secondary amino groups. The polymer matrix is e.g. crosslinked dextran, cellulose, polyvinyl alcohol, polyacrylamide, agarose, etc., wherein crosslinked dextran is most preferable. When the polymer matrix is treated with a polyfunctional substance such as epichlorohydrin, a reactive polymer bead can be prepared. The reactive polymer bead obtained by the above process is made to react with a polyfunctional compound having primary or secondary amino group to obtain, almost quantitatively, a positively charged polymer bead free from quaternary amine.
Formaldehyde cyanohydrin is stabilized by the addition thereto of one or more organic acids having a dissociation constant within the range of from 1.0 X 10-2 to 1.0 X 10-4, e.g. mono- or di-chloracetic, bromacetic, thioglycollic, chlorpropionic, lactic, a -hydroxyisobutyric and sulphanilic acids.  In place of the organic acids there may be used substances which under the prevailing conditions react to form the organic acids such as their acid chlorides which are hydrolysed by water present in the cyanohydrin or mineral acids and salts of the organic acids.  A mixture of organic acids may be used such that when the crude cyanohydrin is distilled one organic acid may be present which is more active in stabilizing the crude material and another which distils over with the cyanohydrin and is better able to stabilize the distillate.  Amounts of from 0.1 to 5 per cent of the organic acids may be used.  Examples are given.  The stabilized cyanohydrin may be used as a solvent for dry spinning processes or the polymerization of vinyl compounds.
Power Health is a 1 session general health promotion program designed to be delivered via the internet in real time by a trained health educator. The sessions focus on healthy life styles, cardiovascular health, and prostate health. Participants also receive information regarding safe sex.
Back extension exercise. Total 10 repetitions in 1 set. Total 3 sets in a session. Total 3 sessions in a week. Total 12 sessions in a month.
A method for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of  Lactobacillus  species, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and may also be encapsulated in a frangible enclosure. Levels of  Roseburia  are preferably increased while the levels of  Akkermansia  spp. in the individual's gut microbiome are reduced. In other embodiments, a therapeutically effective amount of a bacterial formulation comprising  Faecalibacterium prausnitzii  is administered, or a composition comprising modified  L. reuteri  bacteria having the ability to survive conditions in the duodenum or jejunum of the individual's small intestine. Other embodiments include the administration of a bacterial formulation comprising at least one of  Coprococcus, Veillonella, Roseburia, Bifidobacterium, Faecalibacterium prausnitzii  and  Prevotella.
Endotracheal intubation plays an important role in contemporary clinical anesthesia. Direct laryngoscope intubation is the traditional intubation method in anesthesia and emergency medical work. However, due to the constraints of the operator's technical level, the abnormal airway structure and the condition of patients, about 1.5% \~ 8.5% of the cases of intubation difficulties occur. It's even impossible to intubate. Failure of intubation can lead to major complications, including brain damage and death. When a tracheal intubation cannot be placed on the first two attempts, the intubation is classified as difficult, and repeated routine tracheal intubation may lead to morbidity in the patient, and the incidence of airway related complications increases significantly with the number of tracheal intubations. Difficult intubation accounted for 4% of operating room intubation and 10% of intubation outside the operating room. For patients with high glottis and short epiglottis, although the glottis can be seen, intubation is difficult to place. The effectiveness and safety of TCI tube assisted intubation under visual laryngoscope and ordinary tube tube assisted intubation in simulated difficult airway were compared to provide reference for clinical application.
The invention discloses a large-aperture composite ultrafilter membrane capable of removing pyrogen. The large-aperture composite ultrafilter membrane capable of removing pyrogen comprises a mixed membrane material. The mixed membrane material is a mixture of a strongly hydrophilic membrane material and a weakly hydrophilic membrane material. The strongly hydrophilic membrane material is one or more of polysulfones, polyethersulfones and sulfonated polysulfones. The weakly hydrophilic membrane material is polyvinylidene fluoride or polyacrylonitrile. The invention also discloses a preparation method and a use of the large-aperture composite ultrafilter membrane capable of removing pyrogen. An application characteristic of the large-aperture composite ultrafilter membrane capable of removing pyrogen comprises realizing an injection pyrogen removal rate above 95% and having no obvious influence on drug active ingredients.
INTRODUCTION: Well-trained staff is needed to interpret cardiopulmonary exercise tests (CPET). We aimed to examine the accuracy of machine learning-based algorithms to classify exercise limitations and their severity in clinical practice compared with expert consensus using patients presenting at a pulmonary clinic.
METHODS: This study included 200 historical CPET data sets (48.5% female) of patients older than 40 yr referred for CPET because of unexplained dyspnea, preoperative examination, and evaluation of therapy progress. Data sets were independently rated by experts according to the severity of pulmonary-vascular, mechanical-ventilatory, cardiocirculatory, and muscular limitations using a visual analog scale. Decision trees and random forests analyses were calculated.
RESULTS: Mean deviations between experts in the respective limitation categories ranged from 1.0 to 1.1 points (SD, 1.2) before consensus. Random forests identified parameters of particular importance for detecting specific constraints. Central parameters were nadir ventilatory efficiency for CO 2 , ventilatory efficiency slope for CO 2 (pulmonary-vascular limitations); breathing reserve, forced expiratory volume in 1 s, and forced vital capacity (mechanical-ventilatory limitations); and peak oxygen uptake, O 2 uptake/work rate slope, and % change of the latter (cardiocirculatory limitations). Thresholds differentiating between different limitation severities were reported. The accuracy of the most accurate decision tree of each category was comparable to expert ratings. Finally, a combined decision tree was created quantifying combined system limitations within one patient.
CONCLUSIONS: Machine learning-based algorithms may be a viable option to facilitate the interpretation of CPET and identify exercise limitations. Our findings may further support clinical decision making and aid the development of standardized rating instruments.
<P>PROBLEM TO BE SOLVED: To provide a technique for exhibiting protective actions on cardiac muscles or blood vessels from peroxide damage by activating protein kinase C without adverse effects and to provide a protein kinase C activator.  <P>SOLUTION: The protein kinase C activator comprises the following glycoprotein. (1) present in royal jelly and forming a single band in an unmodified polyacrylamide gel electrophoresis, (2) having about 57 kDa molecular weight measured by an SDS-polyacrylamide gel electrophoresis under reducing conditions and (3) containing an amino acid sequence of amino acid numbers 1-8 of sequence number 1 (refer to the specification). A composition is obtained by including the protein kinase C activator in a composition for oral administration. Thereby, the technique for exhibiting the protective actions on the cardiac muscles or blood vessels from the peroxide damage by activating the protein kinase C without the adverse effects can be provided.  <P>COPYRIGHT: (C)2004,JPO